Just a few years after the first gene therapies were approved for the market, more than 1,000 new therapies are in clinical trials to determine whether they can beat rare and often fatal inherited disease.
Patients are waiting – and a Columbus biotech manufacturer started operating this month to ease the severe shortage in capacity to make the engineered genes and viruses that deliver them.
Furthermore, Andelyn Biosciences Inc. has the ability to turn around projects in three to five months…
